Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Consolidated Net Income: 2009-2024

Historic Consolidated Net Income for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to $16.9 million.

  • Gyre Therapeutics' Consolidated Net Income rose 107.84% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 112.80%. This contributed to the annual value of $16.9 million for FY2024, which is 119.58% up from last year.
  • According to the latest figures from FY2024, Gyre Therapeutics' Consolidated Net Income is $16.9 million, which was up 119.58% from -$86.3 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Consolidated Net Income registered a high of $16.9 million during FY2024, and its lowest value of -$87.9 million during FY2021.
  • Its 3-year average for Consolidated Net Income is -$22.0 million, with a median of $3.4 million in 2022.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first slumped by 2,620.85% in 2023, then soared by 119.58% in 2024.
  • Yearly analysis of 5 years shows Gyre Therapeutics' Consolidated Net Income stood at -$56.3 million in 2020, then tumbled by 56.10% to -$87.9 million in 2021, then skyrocketed by 103.89% to $3.4 million in 2022, then tumbled by 2,620.85% to -$86.3 million in 2023, then skyrocketed by 119.58% to $16.9 million in 2024.